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Abstract
The human thromboxane A2 receptor (TP), belongs to the prostanoid subfamily of Class A GPCRs and mediates
vasoconstriction and promotes thrombosis on binding to thromboxane (TXA2). In Class A GPCRs, transmembrane (TM) helix
4 appears to be a hot spot for non-synonymous single nucleotide polymorphic (nsSNP) variants. Interestingly, A160T is a
novel nsSNP variant with unknown structure and function. Additionally, within this helix in TP, Ala160
4.53 is highly conserved
as is Gly164
4.57. Here we target Ala160
4.53 and Gly164
4.57 in the TP for detailed structure-function analysis. Amino acid
replacements with smaller residues, A160S and G164A mutants, were tolerated, while bulkier beta-branched replacements,
A160T and A160V showed a significant decrease in receptor expression (Bmax). The nsSNP variant A160T displayed
significant agonist-independent activity (constitutive activity). Guided by molecular modeling, a series of compensatory
mutations were made on TM3, in order to accommodate the bulkier replacements on TM4. The A160V/F115A double
mutant showed a moderate increase in expression level compared to either A160V or F115A single mutants. Thermal
activity assays showed decrease in receptor stability in the order, wild type.A160S.A160V.A160T.G164A, with G164A
being the least stable. Our study reveals that Ala160
4.53 and Gly164
4.57 in the TP play critical structural roles in packing of
TM3 and TM4 helices. Naturally occurring mutations in conjunction with site-directed replacements can serve as powerful
tools in assessing the importance of regional helix-helix interactions.
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Introduction
Membrane receptors present on the cell surface mediate the
communication between the cell and its environment. The largest
group of these membrane receptors belong to the family of G-
protein coupled receptors (GPCRs) [1]. GPCRs contain seven
transmembrane helices (TM) and are activated by diverse
extracellular stimuli including hormones, tastants, light, peptides
and neurotransmitters. The majority of GPCRs belong to the
Class A family and are important pharmacological targets, with
40–50% of prescription drugs targeting these receptors. The
human thromboxane A2 receptor (TP) belongs to the prostanoid
subfamily of Class A GPCRs, and is primarily activated by the
prostanoid, thromboxane A2 (TXA2). TP mediates thrombosis and
vasoconstriction, thereby playing an important pathophysiological
role in heart disease and stroke [2,3].
The receptor knockout studies have implicated TXA2 as a key
regulator of atherosclerosis. Surprisingly little is known about the
influence of TP gene (TBXA2R) variations on cardiovascular
disease. With TXA2 being a powerful airway constrictor, the
major research has focused on the association of variants with
severity and susceptibility to asthma [4],[5] [6],[7] and atopic
dermatitis [8,9]. Structural studies on TP are very limited and few
have addressed the functional significance of the polymorphic
variants in this receptor [10,11,12,13]. A point mutation (R60L) in
the first cytoplasmic loop of the TP, however, has been identified
in an autosomal dominant bleeding disorder characterized by
defective platelet response [14] and another mutation D304N was
also associated with bleeding [13]. None of these studies have
provided the details for structural perturbations or evidence for
constitutive activity as outlined in our study.
Recent crystal structures and mutational studies of rhodopsin and
the b2-AR show that TM1-TM4 form a helical bundle core, with
other helices moving around this core upon activation [15,16,17].
Homo- and heterodimerization studies on GPCRs have shown that
TM4 is an important part of the dimer interface [18,19]. TM4 is
one of the shortest helices in GPCRs, yet it performs important
structural and functional roles and is a hot spot for naturally
occurring GPCR variants. More than 700 GPCRs are identified in
the human genome, with a substantial number of these harbouring
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well as single nucleotide changes referred to as single nucleotide
polymorphisms (SNP). SNPs aresequence changes that canresult in
either synonymous (i.e. change in DNA sequence but no change in
amino acid sequence) or non-synonymous (change in DNA and
amino acid sequence) mutations.
Mutations that affect protein structure and function tend to
occur at evolutionarily conserved sites and are usually buried in
protein structure [21]. One such region in Class A GPCRs, is the
TM4 from residues 4.53 to 4.57 (numbering according to
Ballesteros and Weinstein nomenclature [22]). For example, in
rhodopsin the non-synonymous (ns) SNP A164V
4.53 destabilizes
helix packing resulting in protein misfolding and causes retinitis
pigmentosa [23], similarly the T164I
4.56 nsSNP in b2-AR is
hypofunctional and is associated with coronary and peripheral
artery disease [24]. In the TP receptor, currently there are 7 ns
SNPs listed in the GPCR natural variant database [20], a G/A
change at position 478 in the nucleotide sequence causes a codon
change from GCG.ACG, resulting in A160T in TM4.
In this manuscript, we target two amino acids present in TM4 of
TP receptor, Ala160
4.53 and Gly164
4.57 for structure-function
analysis (Figure 1). These residues are of particular interest for
multiple reasons, the region is highly conserved in Class A GPCRs
(categorized as group-conserved residues) [17,25], with conserva-
tion of up to 99% when considered as a group of small and weakly
polar residues (Gly, Ala or Ser). These amino acids have been
identified in membrane proteins as key determinants in helix-helix
interactions [26]. Furthermore, A160T is a novel nsSNP in TP that
is yet to be characterized and Gly164 is present in close proximity,
just one helical turn away and towards the extracellular surface. In
this study, mutants were generated by site-directed mutagenesis and
transiently expressed in COS-1 or HEK293T cells, and ligand
binding assays were performed using membrane preparations. To
elucidate the effect of these mutations on G-protein signaling,
changes in intracellular calcium levels were measured following
stimulation by agonist U46619. Agonist-independent signaling was
also measured to assess constitutive activity. Guided by molecular
modeling, a series of compensatory mutations were made on TM3,
in order to accommodate the bulkier replacements (example,
replacement with valine) at positions 4.53 and 4.57 on TM4. Our
results show that Ala160
4.53 and Gly164
4.57 in TP receptor form a
packing motif and have a structural role in the tight packing of
helices TM4 and TM3. The A160V/F115A double mutant showed
a moderate increase in expression level compared to either A160V
or F115A single mutants. The nsSNP variant A160T decreased
receptor stability and demonstrated increased affinity towards the
agonist U46619. Both the A160T and A160V mutants displayed
agonist-independent signaling. Furthermore, molecular modeling
Figure 1. Two-dimensional representation of the TPa amino acid sequence. Amino acids are shown in single-letter codes. Shown are the
seven transmembrane helices, the disulphide bond between the Cys102 and Cys183 (green colored residues), the N-glycosylated residues Asn4 and
Asn16 (orange colored residues), and the rho-1D4 octapeptide epitope tag at the C-terminus. The two conserved residues Ala160
4.53 and Gly164
4.57
on TM4 along with the residues on TM3 mutated in this study are shown in red.
doi:10.1371/journal.pone.0029996.g001
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of TM4 causes loss of hydrogen bonding contact of Ser191 in the
extracellular loop-2 (ECL2) with antagonist SQ 29,548. Previous
studies have shown that the residues on ECL2 in TP receptor are
important for SQ 29,548 binding [11,27].
Materials and Methods
Materials
The detergent n-dodecyl-b-D-maltoside (DM) was purchased
from Anatrace (Maumee, OH, USA). Fetal Bovine Serum and
Dulbecco’s Modified Eagle Medium high glucose were purchased
from Sigma and Invitrogen. The TP antagonist [
3H] SQ 29,548
was purchased from PerkinElmer (NET936250UC, PerkinElmer,
MA, USA). Unlabelled TP antagonist SQ 29548, and agonist
U46619 was purchased from Cayman Chemicals Company
(Michigan, USA). Protease inhibitors and common chemicals
were purchased either from Fisher or Sigma. Buffers used were as
follows: phosphate-buffered saline (PBS) buffer: 137 mM NaCl,
2.7 mM KCl, 1.8 mM KH2PO4, and 10 mM Na2HPO4 (pH 7.4);
buffer A (lysis buffer), 10 mM Tris-HCl, pH 7.4, containing
protease inhibitors (1 mM ethylenediaminetetraacetic acid
(EDTA), 10 mg/ml benzamidine, 10 mg/ml leupeptin, 20 mg/ml
soybean trypsin inhibitor, 5 mg/ml aprotinin, and 0.2 mM
phenylmethylsulfonyl fluoride); buffer B (storage buffer) 50 mM
Tris-HCl, pH 7.4, 12.5 mM MgCl2, and containing protease
inhibitors as in buffer A; buffer C (binding buffer), 75 mM Tris-
HCl, pH 7.4, 12.5 mM MgCl2, and containing protease inhibitors
as in buffer A; buffer D, 20 mM Tris-HCl, pH 7.4, containing
100 mM NaCl, and 1 mM EDTA.
Molecular Biology and Cell culture
Amino acid substitutions were introduced into the synthetic
TPa gene carried by the expression vector pMT4 as described
previously [28,29]. DNA sequences of all the mutated genes were
verified by automated DNA sequencing. To minimize variations
in transfection efficiency, the total amount transfected DNA was
kept constant in all cases at 1 mg of DNA per 7610
5 cells. The wild
type TP or mutant genes were expressed in COS-1 cells using a
DEAE-dextran based transient transfection method [28,29], and
in HEK293T cells using lipofectamine 2000 (Invitrogen). Except
unless specified, the membranes prepared from COS-1 cells were
used for radioligand binding assays and immunoblots. For
intracellular calcium determination assays and immunofluores-
cence imaging, HEK293T cells were used. For transient
transfections of HEK293T cells using the plasmid pMT4,
lipofectamine 2000 (Invitrogen) mediated transfection was used
as described by the manufacturer. Membranes were prepared
using Buffers A and B and as described previously [28,29]. The
protein concentration in the resuspended membrane pellet was
determined using a modified DC protein assay kit from Bio-Rad
Laboratories (Hercules, CA).
Radioligand binding assays
These were carried out in Buffer C for 60 min at room
temperature, using 2 to 20 mg of membrane protein and different
concentrations of [
3H] SQ 29,548 (0.5 nM to 20 nM). Binding of
[
3H] SQ 29,548 in the presence of 10 mM SQ 29,548 was used as
a measure of nonspecific binding. Competition binding assays
were performed using 4 nM [
3H] SQ 29,548 and different
concentrations of unlabeled agonists (10
23–10
29 M) and the
reactions kept for 2 hr at room temperature. Binding was
terminated by filtering under vacuum on GF/A filters (Millipore).
Filter-bound radioactivity was measured using a liquid scintillation
counter. Equilibrium dissociation constants (Kd) were determined
from saturation isotherms using PRISM software version 5.0
(GraphPad Software Inc, San Diego, CA, USA). The Ki values
were calculated from the IC50, using the equation of Cheng and
Table 1. Summary of ligand binding properties of wild type TP and mutants*.
Receptor Transmembrane helix Kd
1 (nM) 95% confidence intervals
Bmax
2
(pmol/mg)
EC50
3
(nM)
WT-TP 3.7 3.02 to 4.44 3.860.3 13.160.8
A160S
4.53 IV 6.3 3.64 to 8.90 5.860.5 9.360.3
A160T IV 4.8 3.17 to 6.42 1.860.4 5.560.3
A160V IV 3.8 1.08 to 6.47 1.960.3 9.560.2
G164A
4.57 IV 5.9 3.88 to 7.99 6.360.4 2.560.2
G164V
| – IV - 38.062.1
F107A
3.27 III 2.6 1.33 to 3.92 1.860.2 2.560.7
V110A
3.30 III 4.6 3.72 to 5.44 1.860.3 2.760.2
F114A
3.34 III 4.5 2.14 to 6.84 1.660.3 1.860.2
F115A
3.35 III 3.2 2.50 to 3.89 1.860.2 2.060.3
A160V/F114A
| – IV/III -
G164V/F107A
| – IV/III -
G164V/V110A
| – IV/III -
A160V/F115A IV/III 5.0 1.83 to 8.13 2.160.4 43.561.5
*The values are expressed as the mean 6 S.E (n=2 to 5 experiments in duplicate), and the experiments are performed using the TP antagonist [
3H] SQ 29,548 as the
radioligand (NET936250UC, PerklinElmer).
| –No significant specific binding to [
3H] SQ 29,548 detected for these mutant receptors under the assay conditions.
1Kd, Affinity of the antagonist SQ 29,548 for the receptor.
2Bmax, Binding maximum of the ligand SQ 29,548 for the receptor. Usually expressed as picomoles of TP per milligram of total membrane protein.
3EC50 the molar concentration of agonist U46619 that produces 50% of the maximal possible effect (calcium mobilized) for TP and mutant receptors.
doi:10.1371/journal.pone.0029996.t001
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statistical significance of the data was evaluated using analysis of
variance (ANOVA) and/or unpaired t test.
Determination of intracellular calcium
Changes in intracellular calcium were measured by using the
fluorescent calcium sensitive dye Fluo-4NW (Invitrogen). After 6–
8 hours of transient transfection of HEK293T cells using
lipofectamine 2000, 100,000 viable cells were plated into each
well of a 96-well tissue culture treated BD-falcon optilux plates.
Cells mock transfected with vector pMT4 alone were used as a
negative control. Following 24 hours of incubation at 37uC, the
media was removed and cells were incubated with the dye Fluo-
4NW (Invitrogen) containing 77 mg/ml of probenecid for 1 hour,
as recommended by the manufacturer. Receptor activation was
determined by measuring changes in intracellular calcium after
application of different concentrations of agonist U46619 for TP
and mutants, using Flexstation-3 fluorescence plate reader
(Molecular Devices, CA, USA) at 525 nm following excitation at
494 nm. Dose–response curves were generated and EC50 values
calculated by nonlinear regression analysis using PRISM software
version 5.0 (GraphPad Software Inc, San Diego, CA) after
subtracting the responses of mock-transfected cells stimulated with
same concentrations of agonists.
For estimation of calcium mobilized using the non-ratiometric
calcium indicator Fluo-4NW, the DF/F ratio which approximately
indicates calcium is calculated using the equation (19), DF/F= (F-
Fbase)/(Fbase -B). Where F is the measured fluorescence intensity of
Fluo-4NW, Fbase is the fluorescence intensity of Fluo-4NW in the
cell before stimulation, and B is the background signal determined
from areas adjacent to the cell. For determination of basal Ca
2+
levels for agonist-independent signaling, the Ca
2+ mobilized (DF/F)
was corrected for receptor expression levels (Bmax in picomoles).
Thermal sensitivity assays
Aliquots containing membranes of TP or mutant receptors were
incubated at 25uC, 37uC and at 42uC for 1 to 5 hrs in buffer C. At
the specified time point, aliquots containing the membranes were
removed from the water bath and the receptors were incubated
with a single saturating concentration (20 nM) of [
3H] SQ 29,548
for 60 minutes at room temperature and binding was terminated
by filtering under vacuum on GF/A filters (Millipore). Filter
bound radioactivity was measured using a scintillation counter.
Binding of [
3H] SQ 29,548 in the presence of 10 mM SQ 29,548
was used as a measure of nonspecific binding. The activity of the
receptor at starting time point (zero) is taken as 100% for the wild
type and respective mutants, and the activity remaining at
different time points is expressed as a percentage of the starting
time point.
Immunofluorescence microscopy
HEK293T cells were seeded into six-well tissue culture plates
containing sterilized poly-L-lysine (Sigma)-coated glass cover-slips
and transiently transfected with TP or the mutant constructs
according to published procedures [30]. Cells were fixed in 3.7%
paraformaldehyde/16PBS buffer for 15 min, then permeablized
with 0.05% triton X-100/16 PBS buffer for 30 min. The cells
were washed and blocked with 16 PBS buffer containing 2%
bovine serum albumin (IgG and Protease free) for 60 min. Briefly,
TP and the mutants were labelled for 90 min using a 1:500
dilution of the mouse-anti-rho-1D4 monoclonal antibody (C-
terminal tagged TP) and a 1:100 dilution of rabbit anti-calnexin
polyclonal antibody (Abcam, MA, USA; endoplasmic reticulum
marker). The transfected cells were washed and incubated with
fluorophore-conjugated secondary antibodies using a 1:2000
Figure 2. Saturation binding assays of wild type TP and the
mutant receptors using the TP antagonist [
3H] SQ 29,548.
Saturation assays with membrane bound TP and the mutant receptors,
TM4 mutants in panel A and TM3 mutants in panel B, were performed
with different concentrations of [
3H] SQ 29,548. A one way ANOVA
analysis without any post hoc test showed that except for G164V in
TM4 there were no significant difference between TP and the mutants
at significance level of p,0.05. The data is from a minimum of three
independent experiments, with each point in duplicate.
doi:10.1371/journal.pone.0029996.g002
Figure 3. Heterologous competition curves of TP and select
mutants using the unlabeled agonist U46619 and antagonist
[
3H] SQ 29,548. The Ki values (mM) are shown in parenthesis.
doi:10.1371/journal.pone.0029996.g003
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dilution of goat anti-rabbit Alexafluor 594 (Invitrogen) for 60 min.
Prolong-antifade gold (Invitrogen, Molecular probes, CA, USA)
was used to mount the coverslips on slides, and the edges sealed
with nail-polish. Representative cells were selected and visualized
using an Olympus BX81 microscope for cytoplasmic or plasma
membrane localization.
Homology modeling
The basal model of the TPa was built by homology modeling
using the crystal structure of b1AR (PDB ID, 2VT4) as template.
The transmembrane regions of TP were modelled using
MODELLER 9V7 [31]. Loops of the receptors were modelled
using loop database of SPDBV4.0.1 [32] based on the available
2D NMR structures of loop regions [33]. Side chains of the
molecules were refined with SCWRL4 database [34]. The whole
molecule was energy minimized by 1000 steps of steepest descent
(SD) and 1000 steps of conjugate gradients by using SPDBV 4.0.1
[32]. Molecular dynamics (MD) simulations were performed for
the basal model with OpenMM Zephyr [35]. The quality of model
was verified using PROCHEK [36]. This model was used for
further mutational and docking studies. The mutants were built
using PyMol, and these models were further simulated with
OpenMM Zephyr.
The model was then docked with either antagonist SQ 29,548
or agonist U46619 using AUTODOCK VINA [37]. The binding
site of ligand on the receptor was defined by forming a cube with
dimensions 60680670 around the protein with a grid point
spacing 0.375 A ˚ and center grid boxes 251.807, 212.467 and
38.921 in X, Y and Z dimensions respectively. We performed 50
runs for each ligand. In each run the best pose or energy
minimized conformation was saved. Finally, all poses were
superimposed and the most frequent orientation of the ligand
was taken as final pose. Receptor ligand complex was further
simulated using Desmond 2.4.2.1 molecular dynamics simulation
software [38].
Figure 4. Characterization of Gaq-mediated signalling of the TP and mutant receptors. The data shows agonist U46619 induced calcium
release for TP, mutants and mock transfected (vector pMT4) HEK293T cells, and is expressed as a percentage of the TP activity. Ala160 mutants (panel
A), Gly164 mutants and mock transfected cells (panel B), TM3 mutants (panel C) and double mutants (panel D). The results are from at least three
independent experiments performed in duplicate.
doi:10.1371/journal.pone.0029996.g004
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The role of TM4 in the thromboxane receptor and prostanoid
receptors in general is unclear. We used a combination of naturally
occurring and site-directed mutations, and molecular modelling
studies to determine the critical role for this highly conserved region
in TP. In humans, TP exists as two isoforms TPa and TPb which
are splice variants of a single gene [39]. These variants differ only in
their intracellular carboxyl terminal regions. As the current study is
focused onresiduesinvolved inhelixpacking and that areconserved
in both the isoforms, the shorter isoform TPa was used. The
conserved residues Ala160
4.53 and Gly164
4.57 are present on the
inward-facing side ofTM4inTP.Elucidating therole ofAla160
4.53,
may also decipher the mechanism of the nsSNP variant A160T.
Our initial strategy was to replace Ala160
4.53 and Gly164
4.57 by
amino acids containingboth small and large molecular volumes and
to study the effect of these replacements upon receptor expression,
activity, and binding of the antagonist SQ 29,548.
Expression and ligand binding properties of TP and
mutants
The ligand binding properties of the TP mutants were
measured using the antagonist SQ 29,548 (Table 1). Conservative
substitutions of Ala160
4.53 and Gly164
4.57 with small amino acids
were better tolerated with the A160S and G164A mutants showing
an increase in expression of functional receptor as quantified by
Bmax values (Table 1), and saturation isotherms in Figure 2. A one
way ANOVA analysis without any post hoc test showed that
except for G164V in TM4 there were no significant difference
between TP and the mutants at significance level of p,0.05.
Replacement with larger amino acids at position Ala160
4.53
caused significant reduction in receptor expression (Figure 2).
Gly164
4.57 was more sensitive with the G164V mutant losing the
ability to bind to the antagonist SQ 29,548 (Figure 2). To verify
whether this loss is due to protein misfolding, G164V immuno-
fluorescence microscopy showed that the receptor was properly
expressed on the cell surface (Figure S1). The A160T and A160V
mutants with bulky b-branched amino acids were expressed at half
of the levels of wild type as reflected by the lower Bmax values
(Table 1). This is in agreement with previous studies on TM4
residues, Ser161
4.53 and Ser165
4.57 of b2-AR, where it was
observed that conservative substitutions with small amino acids
such as alanine to serine had a minimal effect on receptor folding
and ligand binding, whereas mutations made to a non-group
conserved amino acid with bulky side chains, such as alanine or
serine to valine and leucine, reduced receptor expression [17,40].
Substitution of the two residues Ala160
4.53 and Gly164
4.57,o n
TM4 with large amino acids may affect the proper packing of the
helices due to steric interactions. If this is the case, introduction of
a second mutation at an appropriate site on an opposing helix may
compensate for the steric clash and restore correct packing. Using
the ligand-free TP molecular model as a template, possible
compensatory mutants were designed by selecting residues within
5A ˚ of Ala160
4.53 and Gly164
4.57, for mutagenesis. In the ligand-
free TP model, Ala160
4.53 is close to Phe114
3.34 and Phe115
3.35,
whereas Phe107
3.27 and Val110
3.30 are in proximity of Gly164
4.57.
Based upon molecular modeling, a series of compensatory
mutations F107A, V110A, F114A and F115A were made on
TM3, in order to try to accommodate the bulkier residues
(Table 1). The single mutants on TM3 bound to antagonist with
affinities similar to TP (Table 1). Additionally they showed
decreased expression levels probably because the large molecular
volumes of the amino acids replaced could not be compensated for
by the smaller volumes which might have affected the local
hydrophobic environment. All the compensatory double muta-
tions except for A160V/F115A lacked the ability to bind to the
antagonist. The A160V/F115A double mutant showed a moder-
ate increase in expression level compared to either A160V or
F115A single mutants. To elucidate whether the double mutants
were misfolded and/or unable to bind to the antagonist,
Figure 5. Characterization of basal or agonist-independent activity. Bar plot representation of the basal amount of calcium released by TP
and mutants per picomole of functional protein expressed (see methods). The G164V mutant could not be assessed as it did not bind to the
antagonist, and the amount of functional receptor could not be calculated. Results are obtained from a minimum of two independent experiments
done in duplicate. The single astrix indicate there is a significant difference in the amount of calcium released at zero concentration of agonist with
respect to wild type TP at significance level p,0.05. Error bars indicate mean 6 SD.
doi:10.1371/journal.pone.0029996.g005
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F115A, G164V/V110A mutants were found localized on the cell
surface. A160V/F114A and G164V/F107A double mutants were
predominantly retained in the intracellular compartments (Figure
S1). This result shows that the G164V/V110A mutant was
properly trafficked to the cell surface but was unable to bind to the
antagonist, resembling the G164V phenotype.
Agonist competition binding assays
We carried out competition radioligand binding assays using the
unlabeled agonist U46619 and antagonist [
3H] SQ 29,548 on
TM4 mutants. Results from the heterologous competition assays
showed that A160S and A160V mutants displayed moderately
increased affinity towards the agonist U46619 with Ki values of
1.52 mM (95% CI, 0.89–2.61) and 1.51 mM (95% CI, 0.89–2.6)
compared to 1.80 mM (95% CI, 1.15–2.60) for TP (Figure 3).
Significant changes were observed for the A160T and G164A
mutants that displayed Ki values of 0.72 mM (95% CI, 0.30–1.66)
and 1.17 mM (95% CI, 0.54–2.52). A one way ANOVA showed
there is a significant difference between the mutants and TP at
significance level of P,0.01 (n=3). The Ki value of G164V
mutant could not be determined because it did not bind to the
antagonist under our assay conditions. While Gly164
4.57 is more
than 7 A ˚ from the TP receptor ligand binding pocket, the changes
observed for the G164A and G164V mutants can be attributed to
the structural influence of amino acid at position 4.57 on the
ECL2 (see modeling). The increase in affinity of A160T for the
agonist U46619 might be due to indirect effects, i.e., changes in
ligand binding pocket or the receptor adopting an active state
conformation, due to perturbation of helical packing by the
A160T mutant. To elucidate the observed differences in agonist
affinities, and decipher whether the mutations affected G protein
coupling or activation, measurement of changes in intracellular
Ca
2+ upon agonist stimulation were pursued.
Intracellular Ca
2+ signalling
Characterisation of Gaq mediated signaling of the TP receptor
and mutants were carried out by measuring the intracellular Ca
2+
flux upon stimulation with agonist U46619 (Figure 4). No
significant variation was found in the EC50 values of A160S and
A160V compared to wild type (Table 1). In agreement with the
agonist competition assays, the A160T mutant showed moderate
increased potency towards the agonist U46619, as illustrated by a
left shift in the dose response (Figure 4A). Significant changes were
seen with the Gly164
4.57 mutants, the G164A demonstrated
increased potency, and G164V mutant showed reduced potency
as demonstrated with a right shift in dose response with agonist
U46619 (Figure 4B). Nevertheless, the G164V mutant reached up
to 90% of wild type activation upon stimulation with higher doses
of agonist U46619.
The TM3 mutants F107A, V110A, F114A and F115A upon
stimulation with agonist U46619 showed an increase in intracel-
lular Ca
2+ flux equivalent to 60–80% of TP generated signal
(Figure 4C). Interestingly, the TM3 mutants displayed a left shift in
the dose response curves, showing that these mutants had
increased potency. Indeed, these mutants displayed 4 to 7 fold
increase in U46619 potency (decrease in EC50 concentration for
half-maximum response) with EC50 values from 1.8 nM to 2.7 nM
compared to EC50 of 13 nM for TP (Table 1). Two double
mutants, one each at positions 4.53 and 4.57 showed agonist
dependent signaling but differed in their dose response character-
istics. The double mutant A160V/F115A showed reduced potency
as demonstrated by a right shift in dose response (Figure 4D). The
G164V/V110A mutant lost SQ 29,548 binding and exhibited a
reduced calcium response which could be restored upon
stimulation with elevated levels of U46619.
Basal Ca
2+ levels of the TP mutants corrected for receptor
expression levels were measured to assess constitutive activity.
Among the TM4 mutants, only bulky b-branched replacements at
position 4.53, A160T and A160V displayed a 2-fold increase in
agonist-independent activity(Figure5).Theconstitutive activityand
the reversal of basal activity for the polymorphic variant A160T was
Figure 6. Thermal sensitivity of wild type TP and select
mutants. It was measured in terms of the ability of the TP and
mutants at positions 4.53 and 4.57 to retain antagonist binding after
incubation at 25uC (panel A), 37uC (panel B) and 42uC (panel C) as a
function of time. The receptor activity decreased in the order,
TP.A160S.A160V.A160T.G164A, with G164A being the least stable.
The results are mean 6SE and are from minimum of three independent
experiments done in duplicate.
doi:10.1371/journal.pone.0029996.g006
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F114A and F115A displayed constitutive activity (Figure 5). This is
not surprising as the mutated residues are towards the extracellular
side of TM3 that is known to play a pivotal role in ligand binding
and activation in many Class A GPCRs [41,42].
Thermal sensitivity assays
To examine the stability of the TM4 mutants, we monitored the
ability of the mutants to retain antagonist affinity after incubation
at 25uC, 37uC and 42uC as a function of time (Figure 6). Thermal
sensitivity of the wild-type or TM4 mutant receptors was
compared to distinguish the contribution of residues at positions
4.53 and 4.57 to stability of the helical core. The wild-type and
mutants A160T, A160S and A160V were stable for 5 hrs at 25uC,
whereas the G164A mutant showed about a 30–40% loss in
antagonist binding (Figure 6A). Thus, differences between the
stabilities of different Ala160 mutants could not be readily
discerned at 25uC. However, thermal stability differences between
the Ala160 mutants were more apparent at higher temperatures of
37uC and 42uC (Figure 6B and C). Within 1 hr at 42uC, mutants
A160T and A160V showed 50–60% loss in total binding similar to
G164A, while wild type and A160S showed only 30% loss in total
binding. Therefore, it appears that the contribution of Gly164 to
receptor stability is very important, and replacement by amino
acids with small molecular volumes such as alanine (G164A)
causing loss of receptor stability. Interestingly, G164A mutant
showed close to two-fold increase in expression of functional
receptor compared to wild type (Figure 2). This result was
surprising as decreased protein stability normally leads to
decreased expression, as is the case with A160T and A160V
mutants. We speculate that the G164A mutant might be resistant
to proteolysis. Data were determined to be statistically significant
using the unpaired student t test at significance level of p,0.05.
Molecular modeling
Molecular models of TP and the TM4 mutants were
constructed to interpret the results in structural terms. Figure 7A
shows the homology model of SQ 29,548 bound TP model
superimposed with the structures of rhodopsin (PDB ID, 1U19)
and antagonist bound b2-AR (PDB ID, 2RH1). The SQ 29,548
bound TP model shows very good homology to rhodopsin and b2-
AR crystal structures with backbone Ca RMSD of 0.4 A ˚ and
1.5 A ˚ for TM4 and TM3 regions analyzed in this study.
The ECL2 has been shown to play an important role in ligand
binding and activation in the TP [11,27] and other Class A
GPCRs [43,44]. Gly164
4.57 occupies a crucial position on the
extracellular side of TM4, and is located at the base of the N-
terminal end of ECL2. In wild type TP and G164A models,
Ser191 and Asp193 were found within the 4 A ˚ region of the
antagonist molecule SQ 29,548. While in G164V model, Asp193
is within the 4 A ˚ region but the crucial hydrogen bond contact
between Ser191 and SQ 29,548 was absent. Mutational studies
Figure 7. Molecular models of antagonist bound TP and G164V mutant and comparison with the crystal structures of rhodopsin
and antagonist bound b2-AR. Panel A, Molecular model of TP bound SQ 29,548 superimposed with the structures of rhodopsin (PDB ID 1U19)
and antagonist bound b2-AR (PDB ID 2RH1). The two residues at positions 4.53 and 4.57 on TM4 in both rhodopsin and b2-AR were previously
studied. For structural comparison all the three structures were superimposed. The color coding is as follows; Ala164 and Ala168 in rhodopsin (red),
Ala160 and Gly164 in TP (blue) and Ser161 and Ser164 in b2-AR (green). Panel B, Molecular models of TP (yellow) and G164V (green) superimposed.
The important amino acids Gly164, Val164 and Ser191 are shown. Notice that Ser191 loses interaction with the antagonist SQ 29,548 in the G164V
mutant.
doi:10.1371/journal.pone.0029996.g007
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on ECL2 resulted in mutants that were incapable of binding to
SQ 29,548 but retained the functional response to treatment with
U46619. This is similar to the G164V phenotype we observed,
and our models validate this interaction (Figure 7B). In wild type,
Ala160
4.53 is packed between Val111
3.31, Phe114
3.34 and
Phe115
3.35. Interestingly, in the A160S mutant the side chain
b-OH of Ser160 interacts with the main chain carbonyl oxy-
group of Trp157
4.50 and no steric hindrance from residues on
TM4 was observed (Figure 8). In A160V and A160T mutants,
the bulky b-branched side chains are intercalated between
Phe114
3.34 and Phe115
3.35. In agreement with the molecular
model, the F115A mutant was able to rescue, albeit partially, the
expression of A160V in the A160V/F115A double mutant
(Table 1). In our model of the A160T mutant, the Thr160 is
more than 8 A ˚ from the ligand binding pocket and is not in a
position to directly interact with the ligand (Figure 7 and
Figure 8), hence the increase in potency observed is due to its
packing interactions with the Phe114
3.34 and Phe115
3.35 on
TM3, which themselves are very sensitive to replacements and
show increased agonist affinity and constitutive activity. There-
fore, the agonist-independent activity observed for the A160T
and A160V mutants is due to the steric clash with Phe114
3.34 and
Phe115
3.35 on TM3 resulting in the receptor adopting an active
state conformation.
Discussion
Role of Ala160
4.53 and Gly164
4.57 in TP
The results presented in this report provide important new
insights into the role of TM4 in prostanoid receptors and in
particular the two conserved residues Ala160
4.53 and Gly164
4.57
present in TM4. The residues at positions 4.53 and 4.57 in the TP
perform predominantly a structural role in packing of TM3 and
TM4 helices. Recently several structures have been reported for
agonist-bound Class A GPCRs, which showed that agonist
induced conformational changes involves rearrangement of the
TM3-TM5-TM6 interface. The recent structural elucidation of a
constitutively active rhodopsin mutant, E113Q present on TM3,
reinforces the central role of TM3 in GPCR activation [15].
However studies that give insights into the structural requirements
for the constitutive and the agonist-induced conformational
changes in TM3 among the prostanoid receptors are unavailable.
In the TP, the G164V replacement was unable to bind to the
antagonist but showed an agonist dose dependent calcium
increase. This phenotype was not observed in rhodopsin and b2-
Figure 8. Molecular models of agonist bound TP and Ala160 mutants. Wild type (panel A), A160S (panel B), A160T (panel C) and A160V
(panel D), and the important amino acids are shown in each model.
doi:10.1371/journal.pone.0029996.g008
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compensatory mutants designed to rescue the expression of
S161V
4.53 were unsuccessful but V114A
3.33/S165V
4.57 double
mutant rescued the expression of S165V
4.57, while in rhodopsin
L119A
3.34/A164V
4.53 rescued the defect in chromophore forma-
tion caused by the retinitis pigmentosa mutant A164V
4.53 [17,23].
However, in the TP we did not observe any protein misfolding
upon mutation of either Ala160
4.53 or Gly164
4.57 residues. This is
in contrast to rhodopsin, where the nsSNP A164V destabilizes
helix packing resulting in protein misfolding and retinitis
pigmentosa [23]. Interestingly, the human red cone opsin
polymorphic variant Ser180Ala (homologous to the rhodopsin
nsSNP A164V) accounts for the subtle difference in normal color
vision and influences the severity of red-green color vision
deficiency [45].
We can speculate as to why the compensatory mutants in TP
were not as successful compared to rhodopsin and b2-AR. In this
study, the compensatory mutations were designed based on
proximity between two amino acids in the molecular model, it is
possible that there is a network of interhelical hydrophobic
interactions involving Ala160
4.53, Phe114
3.34and Phe115
3.35, while
subtle changes are tolerated (mutations to smaller amino acids) any
major change (replacement with larger residues or double
replacements) would disturb this hydrophobic network causing
changes to the ligand binding pocket in the TP.
Polymorphic variant Ala160Thr
Studies have shown that more than 80% of the disease causing
mutations affects protein stability [46]. Similar to the decreased
thermal stability and constitutive activity observed for the nsSNP
A160T, a recent study on the rhodopsin retinitis pigmentosa
mutant, G90V, shows that it has low thermal stability in the dark
state and is constitutively active [47]. Analysis of the protein
sequences revealed that disease causing SNPs tend to occur at
conserved sites [48]. The transmembrane region from residues
4.53 to 4.57 in Class A GPCRs, consist of amino acids with small
molecular volumes that are highly conserved. While this region is
well studied in the opsin and amine subfamilies of Class A GCPRs,
and the disease causing nsSNPs characterized, comparable studies
in the prostanoid subfamily have not been pursued thus far.
Amino acid sequence analyses of 46 TP sequences showed 81% to
have alanine at 4.53 and 85% have glycine at position 4.57. The
other residues were serine (16%) at 4.53 and alanine (13%) at 4.57,
both amino acids with small molecular volumes. Our study reveals
a structural role for the nsSNP A160T variant, while the clinical
significance of this nsSNP remains to be determined.
In conclusion, we show that the two conserved residues
Ala160
4.53 and Gly164
4.57 perform a structural role by enhancing
interhelical packing, and in stabilizing the inactive conformation of
the receptor. A bulky residue at position 4.57 as in the G164V
mutant perturbed helical packing causing decreased protein
stability but also influenced the interaction between amino acids
on ECL2 and the antagonist. This result implies that Gly164
4.57
indirectly affects ligand binding in TP. Our results reveal the
molecular mechanism of the nsSNP variant A160T and show that
it has a destabilizing effect on the TP protein structure and causes
the receptor to adopt an active state conformation. Together, the
results presented above indicate that the study of naturally
occurring mutations in conjunction with site-directed mutagenesis
can serve as powerful tools in assessing the importance of regional
helix-helix interactions in GPCRs and other integral membrane
proteins.
Supporting Information
Figure S1 Cellular localization of the wild type TP and
mutants in HEK293T cells. Double-label immunofluorescence
was performed using mouse monoclonal anti-rho-1D4 antibody
which recognizes the C-terminal octapeptide tag on the expressed
receptors, and rabbit polyclonal anti-calnexin antibody which
localizes to the endoplasmic reticulum (ER). The wild type and
mutant receptors were visualized using goat anti-mouse Alexafluor
488 secondary antibody (panel A) and the ER was visualized with
goat anti-rabbit Alexafluor 594 secondary antibody (panel B). The
overlay of the receptor and ER is shown in panel C (location of the
expressed receptor is indicated by an arrow).
(TIF)
Figure S2 A. Effect of receptor density on basal Ca
2+
mobilization. WT-TP (blue line) and A160T (green line) constructs
were expressed in HEK293T cells at different receptor densities by
varying amounts of DNA used in each transfection (3 mgt o9mg
DNA per 10
5 cells). Receptor expression levels were determined
by radioligand binding assays using a single saturating concentra-
tion (20 nM) of [
3H] SQ 29,548. The slope of WT-TP was
0.00273260.001595 of calcium mobilized (DF/F)/pmol of
receptor while that of the A160T was 0.100160.04041. B.
Reversal of basal activation. Agonist-independent calcium mobi-
lization for WT-TP and A160T (grey bars), and calcium release
after cells were pre-treated with 1 mM of unlabelled antagonist SQ
29,548 (black bars). Unpaired students t test between A160T basal
calcium mobilization and A160T pre-treated with SQ 29,548
showed a significant decrease in basal activity at p,0.05. Similar
results were obtained for WT-TP. The results are from 2
independent experiments done in triplicate and are represented
as Mean 6 SD.
(DOC)
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